Results 181 to 190 of about 212,640 (241)

Starch-Coated Superparamagnetic Fe₃O₄ Nanoparticles: From Physicochemical Characterization to Cytogenetic Assessment in <i>Triticum aestivum</i> L. [PDF]

Nanomaterials (Basel)
Racuciu M, Barbu-Tudoran L, Grigoras M, Brinza F, Oancea S, Creanga D.   +5 more
europepmc   +1 more source

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

European Journal of Haematology, EarlyView.
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner, Lina S. Silva‐Bermudez, Mahmoud Ghazal, Mohammed Abba, Catharina Gerhards, Georgia Metzgeroth, Alice Fabarius, Stefan Klein, Sebastian Kreil, Nanni Schmitt, Patrick Wuchter, Wolf‐Karsten Hofmann, Alexander Streuer   +12 more
wiley   +1 more source

The Diagnostic Evolution of Haematological Neoplasms: A Narrative Review of the Road to Two Genetically Focused Classification Systems Through a Resource-Limited Perspective. [PDF]

Diagnostics (Basel)
Benjamin C, Chapanduka ZC, Rapiti N.
europepmc   +1 more source

SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver

European Journal of Haematology, EarlyView.
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera, Izabela Cymer, John Quinn, Phillip T. Murphy, Patrick Thornton, Niamh McAuley, Harmony Black, Omar Abdelzaher, Catherine Duane, Tatiana Cichocka, Eva Szegezdi, Meegahage Perera, Gerard M. Crotty, Michelle Connolly, Aileen Walsh, Ruth Clifford, Janusz Krawczyk, Teresa Meenaghan, Vitaliy Mykytiv, Ezzat Elhassadi, Mark Coyne, Robert J. Cummins, Rowan Kuiper, Michael O'Dwyer, Siobhan V. Glavey   +24 more
wiley   +1 more source

Acute Myeloid Leukemia with Myelodysplasia-Related Gene Mutations. [PDF]

J Clin Med
Testa U.
europepmc   +1 more source

Intensive Versus Non-Intensive Therapy in Older Patients with Acute Myeloid Leukemia: A Real-World Experience. [PDF]

Medicina (Kaunas)
Yuksekli DE, Bayar A, Uzunoglu Guren C, Arikan F, Temiz F, Yanik AM, Toptas T, Kaygusuz Atagunduz I, Tuglular T, Yilmaz AF.   +9 more
europepmc   +1 more source

Expert Consensus on the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria (PNH): An Algorithmic Approach in an Era of New Treatments

European Journal of Haematology, EarlyView.
ABSTRACT Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder caused by a defect of glycosylphosphatidyl‐anchored proteins, leading to an uncontrolled complement‐mediated hemolysis. The advent of complement inhibitors in clinical practice radically changed patients' outcomes and survival.
Bruno Fattizzo, Monia Marchetti, Elisa Cannizzo, Arianna Gatti, Massimo Geuna, Anna Paola Iori, Maddalena Raia, Simona Sica, Francesco Buccisano   +8 more
wiley   +1 more source

Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis

European Journal of Haematology, EarlyView.
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley   +1 more source

A rare <i>de novo</i> prenatal case of Down syndrome due to der(21;21)(q10;q10). [PDF]

Arch Clin Cases
Manea-Sabau ID, Curici A, Lucuta L, Ciurea T, Riza M, Suciu-Lazar V, Anton R, Ceausu I.   +7 more
europepmc   +1 more source

Patient and Healthcare Provider Satisfaction With Subcutaneous Versus Intravenous Administration of Daratumumab in Combination With Lenalidomide and Dexamethasone as First‐Line Treatment in Patients With Newly Diagnosed Non‐Transplant Eligible Multiple Myeloma: Final Results of the MYLENE Study

European Journal of Haematology, EarlyView.
ABSTRACT Objectives The MYLENE non‐interventional study (NIS) aimed to close the gap in real‐world data on the experience and satisfaction with subcutaneous (sc) and intravenous (iv) daratumumab application in patients with newly diagnosed non‐transplant eligible multiple myeloma in Germany.
Eyck von der Heyde, Marcel Reiser, Vanessa Baumgartner, Christian Englisch, Oliver Frank, Sabrina Buchholz, Fabian Kreimendahl, Jens Uhlig, Dieter Bürkle, Wolfgang Knauf   +9 more
wiley   +1 more source